Former Chief Medical Officer · Kalaris Therapeutics, Inc. (KLRS)

Agustin Melian

FY2021 is the first fiscal year CompBrief holds for Agustin Melian as a named executive officer of Kalaris Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$5,830,095

Salary $553,000Stock awards $1,844,063

4th of 5 named executive officers at Kalaris Therapeutics by FY2021 total.

5 named officers on file for Kalaris Therapeutics, FY2021

Agustin Melian’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kalaris Therapeutics’s whole pay program stands against its peers

  • Kalaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KLRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 6, 2022 (DEF 14A).

Free

Get Agustin Melian’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Agustin Melian compensation by year

Kalaris Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Kalaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$553,000
Bonus$0
Stock awards$1,844,063
Option awards$2,620,820
Non-equity incentive$0
Pension and deferred compensation$0
All other$812,212
Total$5,830,095

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kalaris Therapeutics, Inc. DEF 14A filed April 6, 2022, accession 0001193125-22-097515, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kalaris Therapeutics, Inc. filed document, accession 0001193125-22-097515. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU199,262$2,578,450—
RSU43,750$566,125—
Option81,250—$42.15
Option151,732—$17.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Kalaris Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Kalaris Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
David HallalChairman and Former Chief Executive Office r$16,797,713
Diana BrainardChief Executive Officer$15,136,121
Vikas SinhaPresident and Chief Financial Officer$6,622,996
Agustin Melian · this pageFormer Chief Medical Officer$5,830,095
Jeroen van BeekChief Commercial Officer$4,172,849

The full Kalaris Therapeutics compensation record

free company brief

This page is one person within Kalaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kalaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Agustin Melian's compensation dossier · One-time report. No refunds.